Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) Income from Continuing Operations (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Income from Continuing Operations readings, the most recent being 2105000.0 for Q4 2017.

  • On a quarterly basis, Income from Continuing Operations rose 43.67% to 2105000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was 13095000.0, a 25.7% increase, with the full-year FY2025 number at 45617000.0, down 26.07% from a year prior.
  • Income from Continuing Operations hit 2105000.0 in Q4 2017 for Eledon Pharmaceuticals, up from 2965000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 883000.0 in Q2 2016 to a low of 13260000.0 in Q1 2015.
  • Median Income from Continuing Operations over the past 5 years was 5700000.0 (2013), compared with a mean of 6000944.44.
  • Biggest five-year swings in Income from Continuing Operations: soared 90.14% in 2016 and later crashed 654.93% in 2017.
  • Eledon Pharmaceuticals' Income from Continuing Operations stood at 5549000.0 in 2013, then dropped by 11.88% to 6208000.0 in 2014, then tumbled by 77.46% to 11017000.0 in 2015, then skyrocketed by 66.08% to 3737000.0 in 2016, then skyrocketed by 43.67% to 2105000.0 in 2017.
  • The last three reported values for Income from Continuing Operations were 2105000.0 (Q4 2017), 2965000.0 (Q3 2017), and 6666000.0 (Q2 2017) per Business Quant data.